ModifiedPremera BluecrossPolicy N/A

Pharmacotherapy of Multiple Sclerosis (Disease-Modifying Therapies)

Criteria for medical necessity, prior authorization, benefit routing, quantity limits, and documentation requirements for disease-modifying therapies used to treat relapsing forms of multiple sclerosis for Premera Bluecross members.

Policy Summary

PayerPremera Bluecross

PolicyPharmacotherapy of Multiple Sclerosis (Disease-Modifying Therapies)

Policy CodePolicy N/A

Change TypeMultiple material updates (added/removed products, formulary and step-therapy revisions)

Effective DateJun 1, 2026

Next Review DateN/A

Key ActionObtain prior authorization and submit office visit notes documenting diagnosis, history, exam, and prior therapy trials when requesting approval.

SourceLink

POLICY UPDATE CHANGES

Added medical necessity criteria for Mavenclad (cladribine) and Mayzent (siponimod) for the treatment of relapsing forms of multiple sclerosis.

Added Tascenso ODT (fingolimod) with identical coverage criteria as Gilenya (fingolimod).

Multiple changes in 2024 and 2025 to site-of-service, age and prescriber requirements, and removal or addition of formulary-specific criteria across many MS drugs.

Extavia (interferon-beta 1b) removed from policy as withdrawn from the market.

Generic cladribine was added to the policy with the same criteria as Mavenclad (cladribine).

Updated Ponvory (ponesimod) coverage criteria to require trial with generic fingolimod and generic dimethyl fumarate first.

Added prescriber and age requirements for multiple listed drugs and clarified quantity limits for several products.

Policy sections and formulary plan mapping were reorganized and references to the Preferred formulary removed.

multipledrug classes covered

≤12 mo

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

<6EDSS threshold (typical)

Multipleformulary updates (2022-25)

Coverage Criteria for Multiple Sclerosis Therapies

General coverage criteria

Covered when ALL of the following are met (drug-specific variations noted):

Core eligibility: Diagnosis of a relapsing form of multiple sclerosis (includes clinically isolated syndrome, relapsing-remitting disease, active secondary progressive disease)

policy applies to relapsing forms

Prescriber: Medication is prescribed by or in consultation with a neurologist or a physician who specializes in the treatment of multiple sclerosis

applies to all drugs listed

EDSS requirement: Individual must have an expanded disability status score (EDSS) below the specified threshold (commonly <6; Mayzent <7)EDSS <6 (Mayzent <7)

see drug-specific criteria

No concurrent DMTs: Medication is not used concurrently with other MS disease-modifying drugs

concurrent use prohibited

Interferons

Interferon class (examples have additional quantity limits):

Avonex (interferon‑beta‑1a): EDSS <6 AND not used concurrently with other MS DMTs AND prescribed by/with neurologistquantity: 4 pens or syringes per 30 days

quantity limit applies

Betaseron (interferon‑beta‑1b): EDSS <6 AND not used concurrently with other MS DMTs AND prescribed by/with neurologistquantity: 14 kits per 30 days

quantity limit applies

Plegridy / Rebif (interferon‑beta‑1a): EDSS <6 AND not used concurrently with other MS DMTs AND prescribed by/with neurologistPlegridy: 2 syringes/pens per 30 days; Rebif: product-specific quantity limits

Glatiramer (copolymer) agents

Glatiramer class:

Glatiramer / Glatopa (generic): EDSS <6 AND not used concurrently with other MS DMTs AND prescribed by/with neurologistquantity: 20 mg/mL — 30 syringes per 30 days; 40 mg/mL — 12 syringes per 30 days

quantity limits as listed

Copaxone (brand) specific: EDSS <6 AND not used concurrently with other MS DMTs AND prescribed by/with neurologist AND documented inadequate response or intolerance to generic glatiramer/Glatopa of same strengthstep: trial of generic glatiramer required before brand

brand requires documented inadequate response or intolerance

Fumarates and Nrf2 pathway activators

Fumarates and related Nrf2 activators:

Bafiertam (monomethyl fumarate): EDSS <6 AND not used concurrently with other MS DMTs AND tried dimethyl fumarate for 3 months with inadequate response or intolerance AND prescribed by/with neurologistdose: 380 mg/day (190 mg twice daily)

prior trial of dimethyl fumarate required

Dimethyl fumarate options: Generic dimethyl fumarate or Tecfidera: EDSS <6 AND not used concurrently with other MS DMTs AND prescribed by/with neurologistdose ≤480 mg/day

Tecfidera may require prior trial of generic dimethyl fumarate

Vumerity (diroximel fumarate): EDSS <6 AND tried dimethyl fumarate for 3 months with inadequate response or intolerance AND not used concurrently with other MS DMTs AND prescribed by/with neurologist

S1P receptor modulators

Sphingosine 1-phosphate receptor modulators:

Generic fingolimod: Age ≥10 years AND EDSS <6 AND not used concurrently with other MS DMTs AND prescribed by/with neurologistdose: 0.5 mg/day; age ≥10 years

age requirement added in recent updates

Gilenya / Tascenso ODT (fingolimod): Age ≥10 years AND EDSS <6 AND prior trial of generic fingolimod with inadequate response or intolerance AND not used concurrently with other MS DMTs AND prescribed by/with neurologistdose: 0.5 mg/day; prior trial of generic fingolimod required for branded products

Tascenso ODT follows identical criteria to Gilenya

Zeposia (ozanimod): EDSS <6 AND not used concurrently with other MS DMTs AND prescribed by/with neurologistdose: 0.92 mg/day; quantity: 30 capsules per 30 days

CD20-directed antibodies and purine antimetabolites

Higher-efficacy agents / special conditions:

Kesimpta (ofatumumab): Age ≥18 years AND EDSS <6 AND not used concurrently with other MS DMTs AND prescribed by/with neurologistage ≥18

quantity limits referenced elsewhere in policy

Cladribine (generic or Mavenclad): EDSS <6 AND not used concurrently with other MS DMTs AND prior inadequate response to one or more disease-modifying drugs (examples listed in policy) AND prescribed by/with neurologistlimited to 2 treatment courses; quantity: 2 tablet packs per 365 days

additional courses beyond two are investigational/not medically necessary

Overview — product-specific medical necessity criteria

Policy includes drug-specific medical necessity criteria that vary by product and by formulary section (Section 1: Incentive/Open/Select; Section 2: Essentials; Section 3: Metallic).

product-level coverage decisions: Specific medical necessity criteria for individual MS disease-modifying therapies (examples: fingolimod, dimethyl fumarate, teriflunomide, cladribine, siponimod, ofatumumab, ocrelizumab, natalizumab, ublituximab, alemtuzumab, ponesimod, ozanimod) are defined in product-specific sections; formulary mapping and site-of-service rules vary by section

See product-specific sections for exact criteria and quantity limits

Step therapy and drug-specific coverage

Coverage is determined per drug with plan-specific sections; certain drugs require trials of specified alternatives prior to approval.

Ponvory coverage: Requires documented trial of generic fingolimod AND generic dimethyl fumarate with inadequate response or intolerance prior to approvaltrial documented

updated 04/01/25 to require both generic trials

Prescriber and age requirement group

Prescriber and age requirements apply for listed products as updated in recent revisions.

Prescriber/age requirements: Specific drugs have added prescriber requirements and age requirements (examples: generic fingolimod, Gilenya, Tascenso ODT, Kesimpta, Avonex, Rebif, Plegridy, Betaseron, glatiramer products, teriflunomide, fumarates, Kesimpta, Mavenclad, Mayzent, Ponvory, Zeposia)prescriber documented; age documented where applicable

See policy history and product sections for exact per-drug prescriber and age rules

The medications listed in this policy are subject to the product's US Food and Drug Administration (FDA) dosage and administration prescribing information. All other uses of the medications listed in this policy that are not consistent with the product's FDA dosage and administration prescribing information are considered investigational and are not covered.

Products that have been withdrawn from the market have been removed from coverage. For example, the Zinbryta section was removed following market withdrawal, and other withdrawn products are similarly excluded from the policy and are not covered.

Extavia (interferon‑beta 1b) has been removed from this policy because it was withdrawn from the market and is no longer covered.

For cladribine products (generic cladribine and Mavenclad), initial and reauthorization language specifies that these products follow the policy's approval periods and review requirements; importantly, all reviews for generic cladribine and Mavenclad following the administration of two treatment courses are considered investigational (i.e., not medically necessary).

The policy previously included several step-therapy or documented inadequate‑response requirements that have since been removed or revised. Notably, the 2024 updates removed certain requirements to document inadequate response or intolerance to specified generics for multiple products, and subsequent updates adjusted required prior DMT trials and related step-therapy language.

The most recent annual review (03/01/26, approved February 9, 2026) recorded no changes to policy statements in that review.

Coding and Quantity Limits

Medical benefit HCPCS codesHCPCS

J1595	Injection, glatiramer acetate, 20 mg (use to report: Glatopa and Copaxone)
J1826	Injection, interferon beta-1a (Avonex), 30 mcg
J1830	Injection interferon beta-1b (Betaseron), 0.25 mg
J3590	Unclassified biologics (use to report: Kesimpta and Plegridy)
Q3027	Injection, interferon beta-1a (Avonex), 1 mcg for intramuscular use
Q3028	Injection, interferon beta-1a (Rebif), 1 mcg for subcutaneous use

HCPCS codes referenced in history and coding updatesHCPCS

J3590	Not all-inclusive; used for certain MS monoclonal antibodies (policy lists multiple biologics under J3590)
Q3028	Added previously for Tascenso ODT (fingolimod) per history
Q5134	Added previously for Briumvi site of service (later removed from policy)
J2329	Previously added to coding table (history)

Dose and quantity limits (examples)

Bafiertam (monomethyl fumarate)Dose limited to 380 mg per day (190 mg twice daily)

Tecfidera (dimethyl fumarate) / generic dimethyl fumarateDose limited to ≤480 mg per day (240 mg twice daily)

Vumerity (diroximel fumarate)Dose limited to ≤924 mg per day (462 mg twice daily)

Fingolimod (generic / Gilenya / Tascenso ODT)Dose limited to 0.5 mg per day

Non‑formulary exception duration

Standard non-formulary exception approval lengthMay be approved up to 12 months

Provider Actions, Prior Authorization, and Documentation

Prior Authorization

Prior Authorization Required

Prior authorization is required for all multiple sclerosis (MS) disease-modifying therapies (DMTs) listed in this policy. Authorization may be issued for up to 12 months when the drug-specific medical necessity criteria are met.

All drugs in this policy require prior authorization.
Initial and re-authorization decisions follow the drug-specific criteria; see each drug section for details.
Non-formulary exception requests may be approved for up to 12 months when criteria and documentation support medical necessity.

Prior Authorization

Prior Authorization and Step/Line-of-Therapy Notes

Many MS DMTs in this policy require prior authorization and, for certain products, specific prior-therapy (step) requirements are applied before approval. New product additions and annual updates may add or change prior-therapy expectations — confirm current criteria at time of request.

Policy updates (2020–2025) added and revised prior-therapy/step requirements for multiple agents (see History and Updates).

Background on Multiple Sclerosis and DMTs

Multiple sclerosis (MS) is an immune‑mediated disease causing demyelination and axonal damage within the central nervous system. It commonly presents in both relapsing and progressive forms; the policy focuses on relapsing forms of multiple sclerosis (including clinically isolated syndrome, relapsing‑remitting disease, and active secondary progressive disease). MS typically affects adults between ages 20 and 50 and is managed using disease‑modifying therapies aimed at reducing relapse frequency and delaying disability progression.

Definitions and Abbreviations

Relapsing forms of multiple sclerosis (policy definition)

Included conditionsClinically isolated syndrome (CIS)

Included conditionsRelapsing‑remitting multiple sclerosis (RRMS)

Included conditionsActive secondary‑progressive multiple sclerosis (active SPMS)

EDSS (Expanded Disability Status Scale) thresholds

EDSS definitionExpanded Disability Status Scale (EDSS)

Common thresholdMost agents require EDSS < 6

Drug‑specific exception

Policy Summary

PayerPremera Bluecross

PolicyPharmacotherapy of Multiple Sclerosis (Disease-Modifying Therapies)

Policy CodePolicy N/A

Change TypeMultiple material updates (added/removed products, formulary and step-therapy revisions)

Effective DateJun 1, 2026

Next Review DateN/A

Key ActionObtain prior authorization and submit office visit notes documenting diagnosis, history, exam, and prior therapy trials when requesting approval.

SourceLink

On This Page

product-specific quantity limits

prior trial of dimethyl fumarate required

quantity limit applies

Mayzent (siponimod): EDSS <7 AND not used concurrently with other MS DMTs AND documented test confirms individual does NOT have CYP2C9*3/*3 genotype AND prescribed by/with neurologistdose: 2 mg/day; EDSS <7; negative CYP2C9*3/*3 required

contraindicated in CYP2C9*3/*3 genotype

Ponvory (ponesimod): EDSS <6 AND prior trials of generic fingolimod AND generic dimethyl fumarate with inadequate response or intolerance AND not used concurrently with other MS DMTs AND prescribed by/with neurologistdose: 20 mg/day; prior trials required

step therapy requires trials of generic fingolimod and generic dimethyl fumarate

Applies toNon-formulary exception requests for drugs listed in this MS DMT policy

Related authorization noteFailure to request appropriate exception or meet formulary requirements may trigger denial

Tascenso ODT (fingolimod) was added with identical coverage criteria to Gilenya (fingolimod).

Removed references to 'first-line' for many agents to reduce confusion about line-of-therapy restrictions.

Prior Authorization

Prior Authorization Duration and Exceptions

Non-formulary exception requests and routine prior authorization approvals may be authorized for up to 12 months when criteria are met. Re-authorization (continuation) may be approved up to 12 months for most drugs when the individual demonstrates a positive clinical response and chart notes document ongoing benefit.

Initial authorization: drugs may be approved up to 12 months.
Re-authorization: most drugs may be approved up to 12 months if documentation shows continued clinical benefit (exceptions: generic cladribine and Mavenclad following two treatment courses are investigational for additional reviews).
Non-formulary exception approvals: may be granted for up to 12 months when criteria and supporting documentation are provided.

Denial Risk

Concurrent Therapy Prohibition

Concurrent use of β-interferons with other MS disease-modifying drugs is not permitted. Requests that indicate concurrent therapy with another DMT should be denied unless clinical justification and a taper/transition plan are provided and meet policy exceptions.

Examples: Avonex, Rebif, Plegridy, Betaseron and other interferon products must not be used concurrently with other MS DMTs.
Concurrent therapy is a denial trigger unless exceptional documentation supports a safe, temporary overlap.

Documentation Required

Required Medical Record Documentation

Required medical record documentation must be submitted with prior authorization requests to demonstrate that the medical necessity criteria are met.

Office visit notes including diagnosis, relevant history, physical exam, and medication history.
Documentation of prior trials (drug names, dates, doses) and evidence of inadequate response or intolerance where a trial is required (e.g., trials of generic fingolimod or generic dimethyl fumarate when specified).
Prescriber specialty and patient age when required by the formulary-specific criteria.

Documentation Required

Formulary-Specific Documentation, Prescriber, and Age Requirements

Formulary section, prescriber, and age requirements vary across plan types (Section 1: Incentive/Open/Select and plans with no pharmacy benefit; Section 2: Essentials; Section 3: Metallic). Ensure the request includes formulary-specific supporting information.

Section 3 (Metallic formulary) has separate or modified criteria for many agents (list updated in 2024).
A prescriber requirement was added in 2025 for multiple agents — include documentation that medication is prescribed by or in consultation with a neurologist or MS specialist when required.
Age requirements added in 2025 for generic fingolimod, Gilenya, Tascenso ODT, and Kesimpta — include patient age on documentation when applicable.

Step Therapy

Required Documentation for Prior-Therapy / Step Requirements

When a drug's coverage criteria require documented trials or attempts with specific generics or other DMTs, submit clear evidence of those attempts. Lack of required documentation is a common denial trigger.

Document trials of specified alternatives (e.g., trial and inadequate response/intolerance to dimethyl fumarate before approving Bafiertam or Vumerity when required).
For Ponvory, document trials and inadequate response/intolerance to generic fingolimod AND generic dimethyl fumarate prior to approval.
Include dates, doses, reasons for discontinuation (intolerance or lack of efficacy), and any supporting clinical notes or labs.

Step Therapy

Step Therapy and Line-of-Therapy Revisions

Policy history includes multiple step-therapy and line-of-therapy revisions. Recent updates clarified removal of 'first-line' language for many agents and updated specific step requirements (notably Ponvory). Verify current requirements against the latest policy version.

2021: Removed 'first-line' wording for many agents to avoid prescribing confusion.
2024–2025: Multiple formulary-specific edits and removal of some prior 'required trials' language for selected agents.
2025: Updated Ponvory coverage criteria to require prior trials of generic fingolimod and generic dimethyl fumarate.

Mayzent allows EDSS < 7

Relapsing‑remitting MS (RRMS)

DefinitionRelapsing‑remitting MS (RRMS): clearly defined acute attacks followed by periods of partial or full recovery

PrevalenceDescribes approximately 85% of individuals with MS

Policy relevanceRRMS is included within 'relapsing forms' referenced by coverage criteria

Primary‑progressive MS (PPMS)

DefinitionPrimary‑progressive MS (PPMS): steady progression without acute attacks; occasional plateaus or remissions possible

PrevalenceApproximately 10% of MS individuals have PPMS

Clinical courseIndividuals do not experience acute attacks

Secondary‑progressive MS (SPMS)

DefinitionSecondary‑progressive MS (SPMS): often follows RRMS with progressively less recovery after attacks and worsening between attacks

Relation to RRMSFollows relapsing‑remitting course in many individuals

Policy inclusionActive SPMS is considered a relapsing form covered by this policy when criteria met

Progressive‑relapsing MS (PRMS)

DefinitionProgressive‑relapsing MS (PRMS): initially presents like PPMS with steady progression, later has superimposed acute attacks followed by partial recovery

PrevalenceRepresents approximately 5% of MS individuals

Clinical noteCharacterized by progression plus later acute relapses

Disease‑modifying drugs (DMTs) — policy definition

Definition used in policyTherapies indicated for first‑ and second‑line treatment options for multiple sclerosis

Policy contextDisease‑modifying drugs (DMTs) are the agents addressed by this coverage policy for relapsing forms of MS

Examples (policy lists)Includes interferons, glatiramer, fumarates, S1P modulators, CD20 antibodies, purine antimetabolites